Peter Nell Email & Phone Number

Peter Nell is a Co-founder, CEO, President at Stealth Mode Biotech based in San Francisco, California, United States, North America. Corporate Strategy • AI/ML Bio Intersection • Business Development & Licensing • Leadership • Drug Discovery, Development and Commercialization • Startups • Pharma Building on my scientific background including as co-inventor of letermovir and neladenoson, I added experience in building companies, business development and licensing, corporate strategy, commercial, alliance management, project management, financing and equity, and many other aspects along the drug discovery process. My background covers small molecules, biologics, RNA therapies, and gene and cell therapy. During the last few years I got more involved in AI-based companies by advising them how to bridge the technical aspects of Artificial Intelligence/Machine Learning with the use in Biology/Pharmacolgy and Drug Discovery with a focus on Business Development and Corporate Strategy. I have worked for ten years in Europe and more than fourteen years in the US. With my strong personal skills in communication, negotiation, strategic thinking, leadership and networking, I gained increasing responsibility at Bayer HealthCare while taken various positions in global locations. In 2016, I co-founded Casebia Tx, a JV between Bayer and CRISPR Tx, the CRISPR company co-founded by Emmanuelle Charpentier. After the successful acquisition of 100% of the partnership interests in Casebia by CRISPR Tx, I joined Mammoth Biosciences, co-founded by Jennifer Doudna, as Chief Business Officer and Head of Therapeutics Strategy. I continue to follow my passion for DNA and RNA editing by exploring new companies in the space and consulting and advising several early stage companies with an additional focus on AI. I have spoken at various public events, government institutions and on conference panels on aspects of gene therapy and gene editing. I was a Program Committee member for the 2025 ASGCT (American Society for Gene and Cell Therapy) meeting in New Orleans.